KRAS alleles: The LCS6 3′UTR variant and KRAS coding sequence mutations in the NCI-60 panel

Cell Cycle

Volumn 11, Issue 2, 2012, Pages 361-366

  Kundu, Samrat T ^a,c   Nallur, Sunitha ^b   Paranjape, Trupti ^b   Boeke, Marta ^b   Weidhaas, Joanne B ^b   Slack, Frank J ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

3 UTR; KRAS; KRAS variant; Let 7; microRNA; SNP

Indexed keywords

DNA; MICRORNA;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CANCER RISK; COLON CANCER; GENE EXPRESSION; GENOTYPE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG CANCER; MELANOMA; ONCOGENE K RAS; OVARY CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER;

EID: 84856082575     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.2.18794     Document Type: Article

References (48)

1. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998; 8:49-54; PMID:9529605; http:// dx.doi.org/10.1016/S0959-437X(98)80061-0.
2. Downward J. Signal transduction. New exchange, new target. Nature 1998; 396:416-7; PMID:9853744; http://dx.doi.org/10.1038/24743.
3. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3:459-65; PMID:12778136; http://dx.doi.org/10.1038/nrc1097.
4. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998; 273:19925- 8; PMID:9685325; http://dx.doi.org/10.1074/ jbc.273.32.19925.
5. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67:7713-22; PMID:17699775; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-1083.
6. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635- 47; PMID:15766527; http://dx.doi.org/10.1016/j. cell.2005.01.014.
7. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69; PMID:16557279; http://dx.doi.org/10.1038/nrc1840.
8. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 2008; 68:8535-40; PMID:18922928; http://dx.doi.org/10.1158/0008- 5472.CAN-08-2129.
9. Keane FK, Ratner ES. The KRAS-Variant Genetic Test As a Marker of Increased Risk of Ovarian Cancer. Rev Obstet Gynecol 2010; 3:118-21; PMID:21364863.
10. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011; 17:3742-50; PMID:21385923; http://dx.doi. org/10.1158/1078-0432.CCR-10-3405.
11. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, et al. A KRAS variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010; 70:6509-15; PMID:20647319; http://dx.doi. org/10.1158/0008-5472.CAN-10- 0689.
12. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, et al. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 2011; 12:377-86; PMID:21435948; http://dx.doi. org/10.1016/S1470-2045(11)70044-4.
13. Weidhaas J, Slack F, Miller N, Harris L, Tuck D, Zhu Y, et al. Association between KRAS rs61764370 and triple-negative breast cancer-a false positive?- Authors' reply. Lancet Oncol 2011; 12:724; http:// dx.doi.org/10.1016/S1470-2045(11)70163-2.
14. Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, et al. A let-7 microRNAbinding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009; 30:1003-7; PMID:19380522; http://dx.doi.org/10.1093/carcin/bgp099.
15. Zhang W, Labonte MJ, Lenz HJ. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter? Ann Oncol 2011; 22:484-5; PMID:21278223; http://dx.doi.org/10.1093/annonc/ mdq704.
16. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011; 22:104-9; PMID:20603437; http:// dx.doi.org/10.1093/annonc/mdq315.
17. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007; 6:1483-91; PMID:17483436; http://dx.doi.org/10.1158/1535- 7163.MCT-07-0009.
18. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 2010; 9:1080-91; PMID:20442302; http://dx.doi.org/ 10.1158/1535- 7163.MCT-09-0965.
19. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67:2456-68; PMID:17363563; http://dx.doi.org/10.1158/0008- 5472.CAN-06-2698.
20. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S. Regulation of angiogenesis and choroidal neovascularization by members of micro RNA- 23~27~24 clusters. Proc Natl Acad Sci USA 2011; 108:8287-92; PMID:21536891; http://dx.doi. org/10.1073/pnas.1105254108.
21. Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, et al. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 2011; 6:20980; PMID:21738599; http://dx.doi.org/10.1371/ journal. pone.0020980.
22. Mathew LK, Simon MC. mir-210: a sensor for hypoxic stress during tumorigenesis. Mol Cell 2009; 35:737-8; PMID:19782023; http://dx.doi.org/10. 1016/j.molcel. 2009.09.008.
23. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 2009; 8:2756-68; PMID:19652553; http://dx.doi.org/10.4161/cc.8.17. 9387.
24. Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, Cantor C, et al. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci USA 2008; 105:4844-9; PMID:18353987; http://dx.doi. org/10.1073/pnas.0712251105.
25. Wang J, Fu L, Gu F, Ma Y. Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep 2011; 26:1295-303; PMID:21785827.
26. Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011; 1815:197-213.
27. Allen TD, Rodriguez EM, Jones KD, Bishop JM. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res 2011; 71:6010-8; PMID:21803744; http://dx.doi.org/10. 1158/0008- 5472.CAN-11-0595.
28. Dotto GP. Notch tumor suppressor function. Oncogene 2008; 27:5115-23; PMID:18758480; http://dx.doi. org/10.1038/onc.2008.225.
29. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333:1154- 7; PMID:21798897; http://dx.doi.org/10.1126/science. 1206923.
30. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33:416-21; PMID:12590261; http://dx.doi.org/10.1038/ng1099.
31. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002; 16:2252-63; PMID:12208848; http://dx.doi.org/10.1101/gad.988902.
32. Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer 2011; In press; PMID:21744479; http:// dx.doi.org/10.1002/pbc. 23202.
33. Lopez-Beltran A, Ordonez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, et al. cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch 2010; 457:555-61; PMID:20821231; http:// dx.doi.org/10.1007/s00428-010-0969-6.
34. Raheem O, Olufemi SE, Bachinski LL, Vihola A, Sirito M, Holmlund-Hampf J, et al. Mutant (CCTG) n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2. Am J Pathol 2010; 177:3025-36; PMID:20971734; http:// dx.doi.org/10.2353/ajpath.2010.100179.
35. Michelotti EF, Tomonaga T, Krutzsch H, Levens D. Cellular nucleic acid binding protein regulates the CT element of the human c-myc protooncogene. J Biol Chem 1995; 270:9494-9; PMID:7721877; http:// dx.doi.org/10.1074/jbc.270.16. 9494.
36. Ha YS, Yan C, Park C, Yun SJ, Moon SK, Choi YH, et al. GSTT1: a marker of the aggressiveness of bladder cancer. Urol Int 2011; 86:41-6; PMID:21079384; http://dx.doi.org/10.1159/000321689.
37. Zhang ZJ, Hao K, Shi R, Zhao G, Jiang GX, Song Y, et al. Glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null polymorphisms, smoking, and their interaction in oral cancer: a HuGE review and meta-analysis. Am J Epidemiol 2011; 173:847-57; PMID:21436184; http://dx.doi. org/10.1093/aje/kwq480.
38. Hiyama T, Yoshihara M, Tanaka S, Chayama K. Genetic polymorphisms and head and neck cancer risk [Review]. Int J Oncol 2008; 32:945-73; PMID:18425322.
39. Vlajnic T, Andreozzi MC, Schneider S, Tornillo L, Karamitopoulou E, Lugli A, et al. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal patients. Mod Pathol 2011; 24:1404-12; PMID:21743435; http://dx.doi. org/10.1038/modpathol.2011.96.
40. Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, et al. Prognostic significance of AMPactivated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 2010; 103:1025-33; PMID:20808308; http://dx.doi. org/10.1038/sj.bjc.6605846.
41. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001; 29:143-52; PMID:11544480; http://dx.doi. org/10.1038/ng731.
42. Leitzell K. Synaptotagmin: is 2 better than 1? J Neurosci 2007; 27:4231-2; PMID:17442806; http:// dx.doi.org/10.1523/JNEUROSCI.0668-07.2007.
43. Jahn JE, Best DH, Coleman WB. Exogenous expression of synaptotagmin XIII suppresses the neoplastic phenotype of a rat liver tumor cell line through molecular pathways related to mesenchymal to epithelial transition. Exp Mol Pathol 2010; 89:209- 16; PMID:20840848; http://dx.doi.org/10.1016/j. yexmp.2010.09.001.
44. Bost F, Diarra-Mehrpour M, Martin JP. Inter-alphatrypsin inhibitor proteoglycan family - a group of proteins binding and stabilizing the extracellular matrix. Eur J Biochem 1998; 252:339-46; PMID:9546647; http:// dx.doi.org/10.1046/j.1432-327.1998.2520339.x.
45. Hamm A, Veeck J, Bektas N, Wild PJ, Hartmann A, Heindrichs U, et al. Frequent expression loss of Interalpha- trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 2008; 8:25; PMID:18226209; http://dx.doi.org/10.1186/1471-2407-8-25.
46. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006; 5:853-67; PMID:16648555; http://dx.doi. org/10.1158/1535-7163.MCT-05-0155.
47. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83:757- 66; PMID:2041050; http://dx.doi.org/10.1093/ jnci/83.11.757.
48. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989; 81:1088-92; PMID:2738938; http://dx.doi. org/10.1093/jnci/81. 14.1088.